Hisse Senetlerindeki Sıralama
#16392
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Ticaret AP Biosciences Inc (6945)
B piyasa değeri ile 6945 fiyatı
Piyasa Değeri AP Biosciences Inc(6945)
Piyasa Değeri: $296.40M
September 2026 itibarıyla AP Biosciences Inc şirketinin piyasa değeri $296.40M. Bu, verilerimize göre AP Biosciences Inc şirketini dünyanın en değerli 16392nd. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
AP Biosciences Inc piyasa değeri geçmişi (2023 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında 6945
| 6945’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.260T
|
+1,774,392.01%
|
|
|
|
|
$4.779T
|
+1,612,085.39%
|
|
|
|
|
$4.017T
|
+1,355,071.84%
|
|
|
|
|
$3.719T
|
+1,254,724.12%
|
|
|
|
|
$2.734T
|
+922,380.34%
|
